Evofem Biosciences (EVFM) Stock Price & Analysis

1,208 Followers

EVFM Stock Chart & Stats

$0.01$0.00(5.83%)

At close: Nov 02 10:30 AM EST

Day’s Range: $0.01 - $0.01
52-Week Range: $0.01 - $0.02
Previous Close: $0.01
Volume: N/A
Average Volume (3M): 491.38K
Market Cap: $768.67K
Enterprise Value: $60.16M
Total Cash (Recent Filing): $317.00K
Total Debt (Recent Filing): $70.39M
Price to Earnings (P/E): ―
Beta: 0.32
Next Earnings: Mar 04, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Gross Margin

The approximately 69% TTM gross margin indicates that Phexxi generates relatively strong product-level economics before operating expenses. If revenue stabilizes and spending becomes more disciplined, this margin profile could support improved operating leverage and a more sustainable commercial model.

Manufacturing Capacity

Adding a second manufacturing source can improve production flexibility and reduce unit costs once regulatory approvals are obtained. Greater capacity also supports anticipated U.S. and international demand, potentially strengthening PHEXX economics and reducing reliance on a single producer.

Product Positioning

Phexxi addresses sexual and reproductive health with an on-demand, non-hormonal contraceptive format. This differentiated positioning gives Evofem a defined product proposition within women’s health and provides a platform for related indications and future commercial development.

Bears Say

Revenue And Profitability

The sharp TTM revenue decline alongside a near negative 98% net margin shows that commercial scale and earnings durability remain unproven. Even with strong gross margins, continued operating losses make results highly sensitive to expense levels and weaken the company’s ability to fund growth internally.

Cash Generation

Negative operating and free cash flow in every period provided means the business has not yet demonstrated self-funding operations. Although recent cash burn improved from earlier years, continued outflows can constrain investment, increase financing needs, and limit resilience through the next several quarters.

Balance Sheet

Negative equity and debt that is large relative to the asset base create a structurally stressed balance sheet. This reduces financial flexibility and raises recapitalization or dilution risk, while limiting the company’s capacity to absorb setbacks or invest without additional external capital.

Evofem Biosciences News

Evofem amends key convertible note financing terms

Evofem Biosciences ( ($EVFM) ) has provided an update. On October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entered into a fifth amendment to their October

1M ago8K EVFM

Evofem Expands PHEXX Manufacturing Capacity for Global Growth

Evofem Biosciences ( ($EVFM) ) has issued an update. On September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou

1M ago8K EVFM

Evofem reports shipment of 500,000th box of PHEXX

Evofem (EVFM) Biosciences announced the shipment of its 500,000th box of PHEXX, the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel. Published first on TheFly – the ultimate

3M agoEVFM

Evofem Biosciences Updates Investors via New Presentation

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences, Inc., a biotechnology company focused on women’s health, periodically shares corporate slide presentations with the investment community

3M ago8K EVFM

Evofem Biosciences Enters New Subordinated Debt Agreement

Evofem Biosciences ( ($EVFM) ) has issued an update. On July 8, 2026, Evofem Biosciences entered into a subordinated promissory note with HUB Cyber Security, Ltd. for $706,304, carrying 12%

4M ago8K EVFM

Evofem reports Q1 EPS (4c) vs. 0c last year

Reports Q1 revenue $0.9M vs. $0.8M last year. “Evofem (EVFM) continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra

6M agoEVFM

Evofem Biosciences Secures Solosec Distribution Deal in Africa

An announcement from Evofem Biosciences ( ($EVFM) ) is now available. On April 24, 2026, Evofem Biosciences, Inc. entered into an exclusive five-year agreement with Clovis Davis Pharmaceuticals, LLC to

6M ago8K EVFM

Evofem enters exclusive distribution agreement with Clovis Davis for SOLOSEC

Evofem (EVFM) Biosciences entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC 2g oral granules in sub-Saharan Africa. SOLOSEC is approved by the U.S. Food and

6M agoEVFM

Evofem Biosciences Amends Convertible Note Financing Terms

Evofem Biosciences ( ($EVFM) ) has provided an announcement. On April 10, 2026, Evofem Biosciences, Inc. and funds affiliated with Adjuvant Global Health Technology Fund entered into a fourth amendment

7M ago8K EVFM

Evofem Biosciences Reports First Year of Operating Profit

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). On March 11, 2026, Evofem Biosciences reported financial results for the fourth quarter and full year 2025, marking its

8M ago8K EVFM

Evofem Biosciences posts updated corporate investor presentation

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences, Inc. reported that it periodically shares slide presentations with the investment community at industry and other conferences

10M ago8K EVFM

Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals

The latest update is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences held its Annual Meeting on November 26, 2025, where various proposals were voted on by the stockholders.

11M ago8K EVFM

Evofem Biosciences Reports Q3 2025 Earnings

Evofem Biosciences, Inc. ( ($EVFM) ) has released its Q3 earnings. Here is a breakdown of the information Evofem Biosciences, Inc. presented to its investors. Evofem Biosciences, Inc. is a

1y agoEVFM

Evofem says FDA Orange Book lists patent for Solosec treatment

Evofem (EVFM) Biosciences announced that a newly-issued U.S. patent which covers SOLOSEC 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and

1y agoEVFM

EVFM FAQ

What was Evofem Biosciences’s price range in the past 12 months?

Evofem Biosciences lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.

What is Evofem Biosciences’s market cap?

Evofem Biosciences’s market cap is $768.67K.

When is Evofem Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Evofem Biosciences’s earnings last quarter?

Evofem Biosciences released its earnings results on Nov 12, 2026. The company reported $0 earnings per share for the quarter.

Is Evofem Biosciences overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Evofem Biosciences pay dividends?

Evofem Biosciences does not currently pay dividends.

What is Evofem Biosciences’s EPS estimate?

Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Evofem Biosciences have?

Evofem Biosciences has 132,530,080 shares outstanding.

What happened to Evofem Biosciences’s price movement after its last earnings report?

Evofem Biosciences reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Evofem Biosciences?

Currently, no hedge funds are holding shares in EVFM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description